Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, and Chronic Lymphocytic Leukemia Research.
Tumor Board-Inspired Multiagent Artificial Intelligence System for Interpreting Oncology Guidelines.
Artificial intelligence in hematology
Autonomous Analysis of Curated Patient Data Using a Large Language Model-Based Multiagent Framework.
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
Thirty-Day Unplanned Hospital Readmissions in Patients With Cancer and the Impact of Social Determinants of Health: A Machine Learning Approach.
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research
A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes.
A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells
Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation